Nai-Kong V Cheung Selected Research

Bispecific Antibodies

1/2022	Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
1/2022	Bispecific antibodies for the treatment of neuroblastoma.
1/2021	T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
1/2021	Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
12/2020	GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
11/2020	Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
11/2020	Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.
1/2018	TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
1/2017	Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.
1/2017	Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nai-Kong V Cheung Research Topics

Disease

113	Neoplasms (Cancer) 01/2022 - 05/2002
113	Neuroblastoma 01/2022 - 05/2002
13	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2003
8	Melanoma (Melanoma, Malignant) 12/2021 - 11/2002
8	Residual Neoplasm 01/2016 - 10/2003
6	Osteosarcoma (Osteogenic Sarcoma) 01/2021 - 02/2004
5	Ewing Sarcoma (Sarcoma, Ewing) 01/2021 - 01/2014
5	Breast Neoplasms (Breast Cancer) 11/2020 - 11/2002
5	Sarcoma (Soft Tissue Sarcoma) 10/2016 - 02/2004
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2015 - 03/2003
4	Leukemia 01/2022 - 11/2003
4	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 01/2005
4	Disease Progression 01/2021 - 11/2004
4	Rhabdomyosarcoma 12/2020 - 10/2005
4	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 05/2016
4	Glioma (Gliomas) 01/2018 - 12/2008
4	Lymphoma (Lymphomas) 01/2015 - 11/2002
3	Desmoplastic Small Round Cell Tumor 01/2021 - 12/2002
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2016 - 09/2004
3	Neuroectodermal Tumors (Neuroectodermal Tumor) 05/2015 - 10/2004
3	Retinoblastoma (Glioblastoma, Retinal) 03/2015 - 01/2013
3	Pain (Aches) 01/2015 - 03/2011
2	Infections 11/2021 - 10/2010
2	Fever (Fevers) 01/2021 - 01/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 11/2020
2	Starvation 11/2020 - 04/2009
2	Central Nervous System Diseases (CNS Diseases) 01/2020 - 05/2019
2	Stomach Neoplasms (Stomach Cancer) 10/2018 - 01/2018
2	Hodgkin Disease (Hodgkin's Disease) 01/2018 - 06/2005
2	Fatigue 01/2018 - 01/2017
2	Medulloblastoma 01/2018 - 01/2017
2	Headache (Headaches) 01/2018 - 08/2013

Drug/Important Bio-Agent (IBA)

36	Monoclonal AntibodiesIBA 12/2021 - 05/2002
27	AntigensIBA 01/2022 - 06/2002
23	Immunoglobulin G (IgG)IBA 01/2022 - 05/2002
15	AntibodiesIBA 01/2022 - 03/2003
15	Bispecific AntibodiesIBA 01/2022 - 01/2014
12	GD2 gangliosideIBA 12/2021 - 06/2002
10	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017 - 07/2003
8	Complement System Proteins (Complement)IBA 12/2021 - 07/2004
8	Proteins (Proteins, Gene)FDA Link 11/2021 - 03/2003
7	CytokinesIBA 01/2022 - 08/2003
7	GangliosidesIBA 12/2021 - 02/2010
7	naxitamab-gqgkIBA 01/2021 - 07/2012
7	Biological ProductsIBA 01/2019 - 08/2003
6	Chimeric Antigen ReceptorsIBA 01/2021 - 01/2014
6	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2021 - 05/2016
6	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 12/2002
6	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 01/2004
5	GlucansIBA 12/2021 - 05/2002
5	Immunoconjugates (Immunoconjugate)IBA 05/2016 - 10/2004
5	Isotretinoin (Accutane)FDA LinkGeneric 01/2016 - 07/2003
5	Topotecan (Hycamtin)FDA LinkGeneric 03/2011 - 08/2003
5	Vincristine (Oncovin)FDA LinkGeneric 01/2011 - 01/2004
5	Messenger RNA (mRNA)IBA 02/2010 - 06/2002
5	(N- acetylneuraminyl)- galactosylglucosylceramide N-acetylgalactosaminyltransferaseIBA 02/2010 - 06/2002
4	beta-GlucansIBA 12/2021 - 05/2002
4	Immune Checkpoint InhibitorsIBA 12/2020 - 07/2017
4	procaine isothiocyanate (PRIT)IBA 01/2020 - 05/2016
4	Pharmaceutical PreparationsIBA 01/2018 - 08/2003
4	Temozolomide (Temodar)FDA LinkGeneric 01/2017 - 11/2006
4	3-Iodobenzylguanidine (Iobenguane)IBA 11/2014 - 03/2003
4	Biomarkers (Surrogate Marker)IBA 10/2014 - 05/2002
4	DNA (Deoxyribonucleic Acid)IBA 12/2013 - 04/2007
4	polyglucosanIBA 03/2013 - 05/2002
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2011 - 01/2004
3	omburtamab I-131IBA 01/2021 - 12/2019
3	Single-Chain AntibodiesIBA 01/2021 - 03/2015
3	Trastuzumab (Herceptin)FDA Link 12/2020 - 01/2017
3	Radioisotopes (Radionuclides)IBA 11/2017 - 10/2004
3	GlycolipidsIBA 10/2016 - 02/2007
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2016 - 05/2002
3	Immunoglobulins (Immunoglobulin)IBA 01/2016 - 12/2008
3	Surface Antigens (Surface Antigen)IBA 06/2015 - 12/2002
3	LigandsIBA 10/2014 - 12/2009
3	CatecholaminesIBA 04/2014 - 03/2003
3	8H9 monoclonal antibodyIBA 12/2008 - 02/2004
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 04/2007 - 03/2003
3	Complement C3b (C3bi)IBA 06/2005 - 05/2002
2	EnzymesIBA 12/2021 - 02/2010
2	Polysaccharides (Glycans)IBA 12/2021 - 03/2013
2	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2021 - 01/2019
2	Transcription Factors (Transcription Factor)IBA 11/2021 - 12/2007
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 01/2018
2	VaccinesIBA 01/2021 - 03/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020 - 01/2017
2	HaptensIBA 01/2020 - 01/2018
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2018 - 04/2005
2	KIR ReceptorsIBA 01/2018 - 01/2016
2	Peptides (Polypeptides)IBA 01/2018 - 05/2004
2	perifosineIBA 01/2017 - 01/2017

Therapy/Procedure

57	Therapeutics 01/2022 - 05/2002
43	Immunotherapy 01/2022 - 12/2002
27	Drug Therapy (Chemotherapy) 01/2022 - 09/2002
20	Radioimmunotherapy 01/2022 - 03/2003
13	Radiotherapy 01/2022 - 07/2003
7	Induction Chemotherapy 01/2018 - 03/2003
4	Precision Medicine 01/2020 - 05/2016
3	Aftercare (After-Treatment) 07/2010 - 07/2003
2	Craniospinal Irradiation 01/2020 - 05/2010